Navigation Links
Pinnacle Biologics, Inc. Announces the Successful Completion of a Financing Round
Date:1/9/2012

BANNOCKBURN, Ill., Jan. 9, 2012  /PRNewswire/ -- Led by NUMODA CAPITAL INNOVATIONS, LLC., PINNACLE BIOLOGICS announced today the succesful completion of a financing round, in a combination of Equity, and Debt Conversion.

"Today's announcement represents another major milestone for Pinnacle Biologics. After completing the acquisition of the Global Photo Dynamic Therapy ("PDT") Business from Aptalis Pharma early last year, Pinnacle continues the process of solidifying its presence in the US Oncology Field, for particularly aggressive forms of cancer, expanding its presence in Europe and emerging markets, and completing the clinical work toward supporting regulatory and clinical development of new indications for PDT globally," said Guillermo Herrera, Executive Chairman and CEO of Pinnacle. In addition, the company remains focused on targeting the acquisition of other specialty pharmaceutical revenue generating products to further accelerate growth and supplement the existing business.

"Pinnacle exemplifies a new model of bio-pharmaceutical companies, with proven management, demonstrated ability to execute, and products with clear upside potential due to expansion of use in existing indications, potential for expansion into new and exciting indications in unmet clinical areas, and global expansion beyond the US and Western European markets," said Patrick Keenan, Chief Counsel and Strategist of Numoda Capital Innovations.

"The proceeds from this financing round coupled with the positive cash flows already generated by the company will be used to support Phase 3 Clinical Trials in cholangiocarcinoma, laryngeal tracheal cancer, and mesothelioma, plus the enhancement of commercial activities to optimize revenue in the current businesses of the company," said Gary Parks CFO of Pinnacle.

ABOUT PINNACLE BIOLOGICS:

Pinnacle Biologics specializes in revitalizing healthcare therapies to fulfill their true potential and to maximize favorable patient outcomes. This is accomplished through licensing and acquisition of specialty pharmaceuticals and medical devices. Our innovative approach to opportunity analysis, business development, lifecycle management, regulatory expertise and distribution leverage takes each product to its highest degree of potential and maximum patient benefit.

FORWARD LOOKING STATEMENT

Except for historical information contained herein, there are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should", "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved.                                                                                               

CONTACT:

Guillermo Herrera
Executive Chairman
Pinnacle Biologics, Inc.
2801 Lakeside Dr - Suite 209
Bannockburn, IL 60015
P: 1.847.283.7690
F: 1.847.283.7695

www.pinnaclebiologics.com
www.photofrin.com


'/>"/>
SOURCE Pinnacle Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Syndication Inc. Seeks DIRECTOR OF TECHNICAL ENGINEERING for PINNACLE ENERGY - Its New Alternative Energy Subsidiary
2. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
3. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
4. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
5. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
6. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
7. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
8. Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
9. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
10. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
11. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... Malden, Mass. (PRWEB) , ... May 18, 2017 ... ... completed the procedure on April 28, 2017 at the Prince Of Wales Private ... degenerative cervical disc at level C6-C7. The patient failed conservative treatments prior to ...
(Date:5/18/2017)... ... 2017 , ... NDA Partners Chairman Carl Peck, MD , announced today ... and President of Pharmaceutical Development Business Unit of Cardinal Health, has joined the firm ... he was former Chief Operating Officer at Anaborex, Senior VP and General Manager of ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... business process optimization firm for the life sciences and healthcare industries, is honored ... and Traceability for Medical Devices conference in Brussels, Belgium. , Crowley played a ...
(Date:5/18/2017)... ... May 17, 2017 , ... ... example, are more likely to develop Alzheimer’s disease, while men are at greater ... for this gender-specific neuronal bias is the aim of a research program at ...
Breaking Biology Technology:
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/24/2017)... Controller General of Immigration from Maldives Mr. Mohamed Anwar and ... international IAIR Award for the most innovative high security ePassport and eGates  ... ... Maldives Immigration Controller General, Mr. Mohamed Anwar ... right) have received the IAIR award for the "Most innovative high security ...
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
Breaking Biology News(10 mins):